A new triple therapy for aggressive, advanced breast cancer delays the progression of the disease by 17.2 months on average, delays the need for further chemotherapy by 2 years and helps patients live longer. 💖💊⏳
Read Full Article
#BreastCancerAwareness #TripleTherapy #CancerResearch #PatientCare #OncologyAdvancements
Read Full Article
#BreastCancerAwareness #TripleTherapy #CancerResearch #PatientCare #OncologyAdvancements
The New England Journal of Medicine
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer | NEJM
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib
plus palbociclib–fulvestrant led to a significant progression-free survival benefit,
as compared with placebo plus...
plus palbociclib–fulvestrant led to a significant progression-free survival benefit,
as compared with placebo plus...